BUSINESS

U3-1402 Racks Up 42.9% Response Rate in Breast Cancer Study: Daiichi Sankyo

December 7, 2018
Daiichi Sankyo’s potential first-in-class HER3-targeting antibody drug conjugate (ADC), U3-1402, delivered an overall response rate of 42.9% in a PI/II study enrolling patients with heavily pretreated HER3-positive metastatic breast cancer, according to the latest data. The updated study results, which…

To read the full story

BUSINESS

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…